News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Dare Bioscience (NASDAQ:DARE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.

Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization

Daré Bioscience Receives $3.6 Million in Additional Grant Funding

Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript [Seeking Alpha]

Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result [Yahoo! Finance]

11/13/2025

04:01 pm

dare

-3.4%

BEAT

8/14/2025

04:01 pm

dare

7.3%

BEAT

5/13/2025

04:01 pm

dare

0.0%

BEAT

Form 8-K Dare Bioscience, Inc. For: Nov 26

Form 1-A Dare Bioscience, Inc.

Form SCHEDULE 13G Dare Bioscience, Inc. Filed by: LAW CUSTODIAL INC.

Top News Decliners

11/21 Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform -16.7%

4/28 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $7.50 price target on the stock. -16.0%

1/30 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule -14.4%

11/12 Form 10-Q Dare Bioscience, Inc. For: Sep 30 -13.6%

5/8 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research -12.9%

12/18 Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study -12.7%

9/11 Dare Bioscience Inc (NASDAQ: DARE) is now covered by analysts at Maxim Group. They set a "buy" rating and a $3.00 price target on the stock. -12.2%

1/23 Dare Bioscience Inc (NASDAQ: DARE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%

4/1 Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene® -10.5%

9/11 Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics -10.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}